VXM 01

Drug Profile

VXM 01

Alternative Names: VEGFR2 peptide vaccine - VAXIMM; VEGFR2 specific T cell vaccine - VAXIMM; VXM-01

Latest Information Update: 08 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck KGaA
  • Developer VAXIMM
  • Class Cancer vaccines; DNA vaccines; Peptide vaccines
  • Mechanism of Action Angiogenesis inhibitors; Immunostimulants; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer; Glioblastoma; Pancreatic cancer
  • Preclinical Solid tumours

Most Recent Events

  • 03 Jun 2017 Interim adverse events, efficacy and immunogenicity data from the phase I trial in Glioblastoma (Late-stage disease, Recurrent, Second-line therapy or greater) presented at the 53rd annual meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 09 May 2017 VAXIMM, Merck and Pfizer agree to co-develop VXM 01, in combination with avelumab, for Glioblastoma and Colorectal cancer
  • 09 May 2017 Vaximm, Merck and Pfizer plans the phase I/II trial for Colorectal cancer(Combination therapy, Metastatic disease)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top